Viewing nowCombinationPimasab Tablet 30/2.5 mg
Fimasartan Potassium Trihydrate 33.005mg · S-Amlodipine Besylate 2.5 Hydrate 3.74mg
Tablet · Prescription medication · Combination
Il Sung IS Co., Ltd.

MFDS item code 202300133 · Approved 2023.01.06 · Insurance code 655404610
Treatment of essential hypertension inadequately controlled with fimasartan potassium monotherapy
Pimasartan potassium is used for patients with essential hypertension who do not have sufficient blood pressure control with monotherapy. This medication helps lower blood pressure by dilating blood vessels, contributing to the reduction of the risk of complications due to hypertension. Therefore, it provides appropriate therapeutic effects for hypertensive patients who have difficulty in managing their blood pressure.
The recommended dose is 1 tablet once daily, taken with water regardless of meals. It is recommended that the tablet be taken at the same time each day, if possible (e.g., in the morning). It is recommended that the dose of fimasartan be adjusted before this medicine is administered. However, if blood pressure is not controlled as described below, switching directly to this medicine may be considered. ㆍ 30/2.5 mg: Administer to patients whose blood pressure is not adequately controlled with fimasartan 30 mg monotherapy. ㆍ 60/2.5 mg: Administer to patients whose blood pressure is not adequately controlled with fimasartan 60 mg monotherapy. ㆍ 60/5 mg: Administer to patients whose blood pressure is not adequately controlled with fimasartan 60 mg monotherapy or this medicine 60/2.5 mg. Patients taking fimasartan and S-amlodipine (amlodipine) concomitantly may switch to this medicine (a combination product containing the same amounts of each active ingredient) for convenience. Elderly patients No initial dose adjustment is required for elderly patients aged 70 years or younger. Patients with renal impairment No dose adjustment is required in patients with mild to moderate renal impairment (creatinine clearance 30 ~ 80 mL/min); however, in patients with severe renal impairment (creatinine clearance < 30 mL/min), treatment should be initiated with fimasartan 30 mg in this medicine. Patients with hepatic impairment No dose adjustment is required in patients with mild hepatic impairment; however, this medicine should not be administered to patients with moderate to severe hepatic impairment.
The safety and efficacy of this medicine have not been established in pediatric and adolescent patients aged 18 years or younger.
This medication can cause serious harm or death to the fetus and newborn if taken during the second and third trimesters of pregnancy, so it should be stopped immediately upon confirmation of pregnancy. This medication should not be used in patients with specific allergic reactions, pregnant or nursing women, patients on renal dialysis, patients with moderate to severe hepatic impairment, patients with biliary obstruction, diabetic patients with specific kidney diseases, patients with specific hereditary lactose intolerance, patients with severe aortic stenosis, and patients in shock. Patients with reduced blood volume or body salts, patients with impaired renal function, patients with renovascular hypertension, patients with aortic and mitral stenosis, patients with primary aldosteronism, patients with severe hypotension, the elderly, and those with a history of allergy to specific dyes in this medication should use it with caution. When taking this medication, side effects such as dizziness, headache, facial swelling, urinary disturbances, insomnia, and flushing may occur, and if any unusual symptoms appear, consulting a doctor is advised. Patients using high-dose diuretics or with reduced blood volume may experience symptoms of hypotension, so particular caution is needed during the initial intake and dosage increase. Patients with impaired renal function may experience changes in renal function, so regular examinations are necessary. This medication may increase the hypotensive effect when used in conjunction with other antihypertensive drugs, so patients must inform their doctor about any other medications they are taking. Pregnant and nursing women are advised to avoid this medication, especially during pregnancy, as it may pose risks to the fetus, and they should consult a doctor before taking it. The safety and efficacy in children under 18 years have not been established, so it is recommended not to use it. In case of overdose, symptoms such as severe hypotension, arrhythmias, and shock may occur, and immediate contact with a medical institution for appropriate treatment is needed. This medication should be kept out of reach of children, and transferring it to another container should be avoided as it may cause degradation of quality or accidents.
Not everyone experiences these, and they can vary from person to person.
This medication is sensitive to light, so it should be stored in a container that prevents light exposure. Additionally, it is important to store it at room temperature, specifically between 1 to 30 degrees Celsius, to maintain its effectiveness.
White film-coated tablet with rounded corners
30 tablets/bottle, 300 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationFimasartan Potassium Trihydrate 33.005mg · S-Amlodipine Besylate 2.5 Hydrate 3.74mg
Tablet · Prescription medication · Combination
Il Sung IS Co., Ltd.
CombinationFimasartan Potassium Trihydrate 66.01mg · S-Amlodipine Besylate 2.5 Hydrate 7.48mg
Tablet · Prescription medication · Combination
Donggu Bio Pharmaceutical Co., Ltd.
CombinationFimasartan Potassium Trihydrate 33.005mg · S-Amlodipine Besylate 2.5 Hydrate 3.74mg
Tablet · Prescription medication · Combination
Donggu Bio Pharmaceutical Co., Ltd.
CombinationFimasartan Potassium Trihydrate 66.01mg · S-Amlodipine Besylate 2.5 Hydrate 3.74mg
Tablet · Prescription medication · Combination
Donggu Bio Pharmaceutical Co., Ltd.
CombinationFimasartan Potassium Trihydrate 33.005mg · S-Amlodipine Besylate 2.5 Hydrate 3.74mg
Tablet · Prescription medication · Combination
NBK Pharmaceutical Co., Ltd.
CombinationFimasartan Potassium Trihydrate 33.005mg · S-Amlodipine Besylate 2.5 Hydrate 3.74mg
Tablet · Prescription medication · Combination
Ajou Pharmaceuticals Co., Ltd.
CombinationFimasartan Potassium Trihydrate 33.005mg · S-Amlodipine Besylate 2.5 Hydrate 3.74mg
Tablet · Prescription medication · Combination
Kips Biopharma Co., Ltd.
CombinationFimasartan Potassium Trihydrate 33.005mg · S-Amlodipine Besylate 2.5 Hydrate 3.74mg
Tablet · Prescription medication · Combination
Bionex Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.